See which 3 stocks are most likely to make moves following their insider activities.
Hcp Incorporated (NYSE:HCP) had a decrease of 15.19% in short interest.
Weighted Alpha is used to calculate how much a share has gone up or down over a certain period, normally a year. The SI to Hcp Incorporated’s float is 2.52%. HCP, Inc. (NYSE:HCP) has risen 8.01% since August 28, 2016 and is uptrending. Schwab Charles Investment Mngmt Inc has 57,300 shares. The company has market cap of $13.77 billion. State Street invested in 530,122 shares.
Investors sentiment increased to 2.06 in Q4 2016. ACRX has a 1-week performance of 0%. 43 funds opened positions while 98 raised stakes. 417.84 million shares or 0.86% less from 421.45 million shares in 2016Q3 were reported. Da Davidson Company invested in 33,500 shares. Transamerica Fin owns 0.06% invested in HCP, Inc. If Allergan plc (NYSE:AGN) shares can stay above the price resistance around $223.41 a share, that could help propel Allergan plc (NYSE:AGN) higher to the next line of resistance at $225.01 a share. St Germain D J Incorporated reported 211,687 shares or 0.85% of all its holdings. Natl Bank Of Ny Mellon stated it has 0.09% in HCP, Inc. Morgan Stanley accumulated 119,249 shares or 0% of the stock. Whittier Of Nevada reported 0.01% of its portfolio in HCP, Inc. (NYSE:HCP). Moreover, New Mexico Educational Retirement Board has 0.16% invested in HCP, Inc. (NYSE:HCP) for 115,100 shares. International Ca has 0.73% invested in Core Laboratories N.V. (NYSE:CLB). Renaissance Techs Lc owns 0.16% invested in HCP, Inc. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. Therefore 50% are positive.
ACRX has been the subject of a number of research analyst reports.
07/14/2017 – Jefferies began new coverage on AcelRx Pharmaceuticals, Inc. giving the company a “buy” rating. BTIG Research initiated the stock with “Neutral” rating in Thursday, August 25 report. The firm has “Hold” rating given on Monday, April 24 by ABN Amro. They now have a Dollars 16.5 price target on the stock. The stock of HCP, Inc. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 15 funds opened positions while 22 raised stakes. Meeder Asset Mgmt Inc holds 6,319 shares. Aberdeen Asset Mgmt Public Limited Com Uk owns 32,322 shares or 0% of their USA portfolio. Grt Capital Prns Ltd Company holds 0.04% or 49,761 shares.
05/12/2015 – AcelRx Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks.
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 0.84% during trading on Friday, reaching $2.95. 8,480 were reported by Manufacturers Life Insur Co The. (NASDAQ:ACRX) in a report released on Friday. Blackrock Institutional Na holds 920,173 shares.
05/06/2015 – AcelRx Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Mizuho. Virtu Limited Liability Company has 2,534 shares. AcelRx Pharmaceuticals has an average rating of “Hold” and an average target price of $7.50.
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.84 in total earnings per share. Therefore 75% are positive. The stock has “Hold” rating by Cowen & Co on Tuesday, August 1. As per Friday, August 4, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating given on Monday, October 5 by TH Capital.
Growth rates are very important while analyzing the long term growth and valuation of a certain company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Friday, August 4th. The industry’s and sector’s high P/E for the past year is 103.66 and 26.47 respectively and low P/E ratio for the last 5 years is 7.11 for the industry and 10.05 for the Sector. Piper Jaffray Companies set a $3.00 price target on shares of AcelRx Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, July 25th. Howland Lc holds 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 10,000 shares.
AcelRx Pharmaceuticals, Inc.is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The stock’s market cap is $133.87 million. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. It now has negative earnings.